Price (delayed)
$4.765
Market cap
$345.01M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.63
Enterprise value
$369.54M
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Fusion connects alpha particle emitting isotopes to targeting molecules in order to selectively deliver the
There are no recent dividends present for FUSN.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.